99780-97-9Relevant academic research and scientific papers
PHENYLPYRROLIDINONE FORMYL PEPTIDE 2 RECEPTOR AGONISTS
-
Paragraph 0238; 0239, (2019/09/16)
The disclosure relates to compounds of Formulae (I)-(IX), which are formyl peptide 2 (FPR2) receptor agonists and/or formyl peptide 1 (FPR1) receptor agonists. The disclosure also provides compositions and methods of using the compounds, for example, for the treatment of atherosclerosis, heart failure, chronic obstructive pulmonary disease (COPD), and related diseases.
ACC INHIBITORS AND USES THEREOF
-
Paragraph 0371, (2017/05/17)
The present invention provides compounds I and II useful as inhibitors of Acetyl CoA Carboxylase (ACC), compositions thereof, and methods of using the same.
N-type calcium channel blockers
-
Page/Page column 24, (2008/06/13)
The invention relates to novel 3-amino pyrrolidine derivatives, as well as methods for modulating calcium channel activity and for treating conditions associated with calcium channel function. In particular, the compounds generally contain at least one be
Inhibitors of prenyl-protein transferase
-
, (2008/06/13)
The present invention is directed to macrocyclic compounds which inhibit prenyl-protein transferase (FTase) and the prenylation of the oncogene protein Ras. The invention is further directed to chemothera-peutic compositions containing the compounds of this invention and methods for inhibiting prenyl-protein transferase and the prenylation of the oncogene protein Ras.
Conformationally Restricted Inhibitors of Angiotensin Converting Enzyme: Synthesis and Computations
Thorsett, Eugene D.,Harris, Elbert E.,Aster, Susan D.,Peterson, Elwood R.,Snyder, James P.,et al.
, p. 251 - 260 (2007/10/02)
A series of inhibitors of angiotensin converting enzyme (ACE, dipeptidyl carboxypeptidase, EC 3.4.15.1) is described which addresses certain conformational aspects of the enzyme-inhibitor interaction.In this study the alanylproline portion of the potent A
